TRVI insider transaction filings
Trevi Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-17. Screen TRVI transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 1 Form 4 filing. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 4 legs across 1 filing by 1 insider — 39,473 shares, $595,806 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 4.
- Largest priced transaction: sale of 20,952 shares @ $15.09 ($316,166) by Heffernan Michael Thomas, filed 2026-09-17.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Heffernan Michael Thomas — Director | 1 | — | 4 legs · 39,473 sh · $595,806 | 4 |
Recent Form 4 filings — Trevi Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | Heffernan Michael Thomas — Director | Option exercise (M): 18,421 @ $3.04 · Sale (S): 18,321 @ $15.09 · Sale (S): 100 @ $15.88 · Option exercise (M): 21,052 @ $3.33 · Sale (S): 20,952 @ $15.09 · Sale (S): 100 @ $15.88 · +2 more | EDGAR |
| 2026-06-04 | 4 | Heffernan Michael Thomas — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Meeker David P — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Mathers Edward T — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Colangelo Dominick — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | VANLENT ANNE — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Simon Farrell — Chief Commercial Officer | Grant/award (A): 160,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Galletta Christopher — See Remarks | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Cassella James V — Chief Development Officer | Grant/award (A): 215,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | SCIASCIA THOMAS — Chief Scientific Officer | Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | GOOD JENNIFER L — President & CEO, Director | Grant/award (A): 675,000 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | HASTINGS DAVID C — Chief Financial Officer | Grant/award (A): 375,000 (derivative) @ $0 | EDGAR |
| 2025-12-03 | 4 | Galletta Christopher — See Remarks | Option exercise (M): 4,225 @ $0.51 · Option exercise (M): 4,225 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Heffernan Michael Thomas — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Meeker David P — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Mathers Edward T — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Colangelo Dominick — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | VANLENT ANNE — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Delfini Lisa — Chief Financial Officer | Grant/award (A): 72,000 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Simon Farrell — Chief Commercial Officer | Grant/award (A): 72,000 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Galletta Christopher — See Remarks | Grant/award (A): 8,550 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | SCIASCIA THOMAS — Chief Scientific Officer | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | GOOD JENNIFER L — President & CEO, Director | Grant/award (A): 102,000 (derivative) @ $0 | EDGAR |
| 2025-03-26 | 4 | SCIASCIA THOMAS — Chief Scientific Officer | Option exercise (M): 2,631 @ $1.43 · Sale (S): 2,631 @ $6.60 · Option exercise (M): 2,631 (derivative) @ $0 | EDGAR |
| 2025-03-25 | 4 | GOOD JENNIFER L — President & CEO, Director | Option exercise (M): 5,263 @ $1.43 · Sale (S): 5,263 @ $6.58 · Option exercise (M): 5,263 (derivative) @ $0 | EDGAR |
| 2025-03-12 | 4 | Delfini Lisa — Chief Financial Officer | Grant/award (A): 38,400 (derivative) @ $0 | EDGAR |
| 2025-03-12 | 4 | Simon Farrell — Chief Commercial Officer | Option exercise (M): 17,500 @ $3.21 · Option exercise (M): 63,813 @ $3.91 · Option exercise (M): 31,250 @ $0.51 · Sale (S): 76,963 @ $6.73 · Sale (S): 4,350 @ $7.15 · Grant/award (A): 38,400 (derivative) @ $0 · +3 more | EDGAR |
| 2025-03-12 | 4 | Galletta Christopher — See Remarks | Grant/award (A): 4,560 (derivative) @ $0 | EDGAR |
| 2025-03-12 | 4 | SCIASCIA THOMAS — Chief Scientific Officer | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2025-03-12 | 4 | GOOD JENNIFER L — President & CEO, Director | Grant/award (A): 54,400 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Simon Farrell — Chief Commercial Officer | Grant/award (A): 225,500 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Delfini Lisa — Chief Financial Officer | Grant/award (A): 225,500 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Galletta Christopher — See Remarks | Grant/award (A): 41,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Cassella James V — Chief Development Officer | Grant/award (A): 257,500 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | SCIASCIA THOMAS — Chief Scientific Officer | Grant/award (A): 116,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | GOOD JENNIFER L — President & CEO, Director | Grant/award (A): 811,000 (derivative) @ $0 | EDGAR |
| 2025-01-10 | 4 | Delfini Lisa — Chief Financial Officer | Option exercise (M): 1,000 @ $0.51 · Option exercise (M): 5,000 @ $0.51 · Option exercise (M): 1,000 (derivative) @ $0 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2024-12-17 | 4 | Galletta Christopher — See Remarks | Option exercise (M): 15,000 @ $0.51 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2024-10-01 | 4 | Cassella James V — Chief Development Officer | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2024-09-09 | 4 | GOOD JENNIFER L — President & CEO, Director | Option exercise (M): 4,219 @ $1.43 · Sale (S): 4,219 @ $3.03 · Option exercise (M): 1,840 @ $1.43 · Sale (S): 1,840 @ $3.04 · Option exercise (M): 4,219 (derivative) @ $0 · Option exercise (M): 1,840 (derivative) @ $0 | EDGAR |
| 2024-09-05 | 4 | GOOD JENNIFER L — President & CEO, Director | Option exercise (M): 3,863 @ $1.43 · Sale (S): 3,863 @ $3.02 · Option exercise (M): 10,981 @ $1.43 · Sale (S): 10,981 @ $3.02 · Option exercise (M): 40,277 @ $1.43 · Sale (S): 40,277 @ $3.11 · +3 more | EDGAR |
| 2024-08-29 | 4 | Meeker David P — Director | Option exercise (M): 4,555 @ $1.43 · Sale (S): 4,555 @ $2.93 · Option exercise (M): 4,555 (derivative) @ $0 | EDGAR |
| 2024-08-21 | 4 | SCIASCIA THOMAS — Chief Scientific Officer | Option exercise (M): 16,496 @ $1.43 · Sale (S): 16,496 @ $2.96 · Option exercise (M): 16,496 (derivative) @ $0 | EDGAR |
| 2024-08-16 | 4 | SCIASCIA THOMAS — Chief Scientific Officer | Option exercise (M): 100 @ $1.43 · Sale (S): 100 @ $2.75 · Option exercise (M): 12,745 @ $1.43 · Sale (S): 12,745 @ $2.79 · Option exercise (M): 18,660 @ $1.43 · Sale (S): 18,660 @ $2.76 · +3 more | EDGAR |
| 2024-06-14 | 4 | Heffernan Michael Thomas — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Meeker David P — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Cassella James V — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Mathers Edward T — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Colangelo Dominick — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | VANLENT ANNE — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Trevi Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-17 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-09 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-12-05 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-11-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-20 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-08-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TRVI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →